Foghorn Therapeutics Cut Jobs and Ended Lilly Deal
The biotech firm terminated its lung cancer drug program after failing to meet efficacy targets.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you plan to continue investing in early-stage biotechnology companies for your portfolio?
Foghorn Therapeutics has ended its joint oncology drug development partnership with Eli Lilly for the candidate FHD-909. Following the program termination, the company is reducing its workforce by 40 percent.
Why it matters
The decision follows trial results showing the drug candidate failed to deliver required efficacy in targeting lung cancer. The company is now pivoting its strategy to preserve its cash reserves.
The FHD-909 program failed to achieve the necessary SMARCA2/4 synthetic lethality efficacy required to enter clinical expansion. Foghorn now retains a reduced staff of approximately 65 full-time employees.
The players
Foghorn Therapeutics
A clinical-stage biotechnology company focused on developing therapies for diseases caused by chromatin regulatory system dysfunction.
Eli Lilly
A major American pharmaceutical corporation that develops and markets medicines in human pharmaceutical health areas.
The details
Foghorn Therapeutics will stop advancing the lung cancer candidate after the phase 1 trial failed to hit performance benchmarks. The board approved this reprioritization on September 30, 2026, leading to a significant reduction in operations.
Timeline
September 30, 2026: The company board approved the strategic reprioritization.
October 1, 2026: The company formally announced the program termination and layoffs.
Second half of 2029: The company expects its remaining cash runway to last until this time.
The Tech Race
This development represents a significant contraction in the competitive space for chromatin-based therapies. The failure forces Foghorn to retreat from the SMARCA2/4 synthetic lethality platform as it attempts to survive a challenging biotech funding environment.
This workforce reduction significantly alters the company's internal capacity to manage ongoing research projects. For investors, the sharp drop in share price reflects immediate volatility and long-term uncertainty regarding the firm's future pipeline viability.
The takeaway
The move underscores the high-risk nature of clinical-stage biotechnology development where efficacy failures often necessitate drastic corporate restructuring. Investors and stakeholders should watch for how the remaining staff prioritizes the company's restricted remaining portfolio.
Further reading
For broader trends in the industry, see the latest updates on Biotech.
Live Poll
Do you plan to continue investing in early-stage biotechnology companies for your portfolio?
